ERBB2 and triple-negative breast carcinoma: The use of menopausal hormone therapy has been consistently associated with an increased risk of luminal A-like breast cancer, but the evidence is less clear for risk of luminal B-like, HER2-positive and triple-negative breast cancer [10, 47, 49].